Clinical Trial Update: A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II study investigating regorafenib in combination with avelumab in various solid tumors, spanning Phase 1 and Phase 2 cohorts.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Colorectal Cancer
• Gastro-enteropancreatic Neuroendocrine Tumor
• Gist
• Hepatocellular Carcinoma
• Hpv-related Carcinoma
• Mesotheliomas Pleural
• Non-small Cell Lung Cancer
• Oesophageal or Gastric Carcinoma
• Renal Carcinoma
• Soft Tissue Sarcoma
• Solid Tumor
• Thyroid Cancer
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• Regorafenib (regorafenib)

Snippet

Sponsor: Institut Bergonié | Conditions: Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1, Phase 2 | Status: UNKNOWN